Thursday, March 2, 2017

Leukemia - Table of Contents alert Volume 31 Issue 3

If you are unable to see the message below, click here to view.

The Bass Center for Childhood Cancer & Blood Diseases at Stanford Children's Health is a leading center for the treatment of leukemia and lymphomas in children. Nationally ranked and part of NCI-designated Stanford Cancer Institute, we're committed to outstanding clinical care, groundbreaking research and state-of-the-art treatment for children with cancer. 

Learn more at 


Volume 31, Issue 3 (March 2017)

In this issue
Original Articles
Letters To The Editor

Also new
Sign up for e-alerts Sign up for e-alerts
Recommend to your library
Web feed
Follow on Twitter
Blood Cancer Journal is an online-only, open access journal, publishing high quality research on hematologic malignancies and related disorders.

Explore the benefits of submitting your next research article.



Do hematopoietic stem cells get old?

J J Jung, S C Buisman and G de Haan

Leukemia 2017 31: 529-531; advance online publication, October 24, 2016; 10.1038/leu.2016.301

Full Text



Responses to pomalidomide and placebo in myelofibrosis-related anaemia

D M Ross

Leukemia 2017 31: 532-533; advance online publication, December 9, 2016; 10.1038/leu.2016.348

Full Text



Preleukemia: one name, many meanings OPEN

H P Koeffler and G Leong

Leukemia 2017 31: 534-542; advance online publication, November 30, 2016; 10.1038/leu.2016.364

Abstract | Full Text

Novel targets in the treatment of chronic graft-versus-host disease

A Im, F T Hakim and S Z Pavletic

Leukemia 2017 31: 543-554; advance online publication, November 30, 2016; 10.1038/leu.2016.367

Abstract | Full Text

Original Articles



Copy-number analysis identified new prognostic marker in acute myeloid leukemia

O Nibourel, S Guihard, C Roumier, N Pottier, C Terre, A Paquet, P Peyrouze, S Geffroy, S Quentin, A Alberdi, R B Abdelali, A Renneville, C Demay, K Celli-Lebras, P Barbry, B Quesnel, S Castaigne, H Dombret, J Soulier, C Preudhomme and M H Cheok

Leukemia 2017 31: 555-564; advance online publication, September 30, 2016; 10.1038/leu.2016.265

Abstract | Full Text

NUP98 is rearranged in 3.8% of pediatric AML forming a clinical and molecular homogenous group with a poor prognosis

S Struski, S Lagarde, P Bories, C Puiseux, N Prade, W Cuccuini, M-P Pages, A Bidet, C Gervais, M Lafage-Pochitaloff, C Roche-Lestienne, C Barin, D Penther, N Nadal, I Radford-Weiss, M-A Collonge-Rame, B Gaillard, F Mugneret, C Lefebvre, E Bart-Delabesse, A Petit, G Leverger, C Broccardo, I Luquet, M Pasquet and E Delabesse

Leukemia 2017 31: 565-572; advance online publication, October 3, 2016; 10.1038/leu.2016.267

Abstract | Full Text


A genome-wide association study identifies risk loci for childhood acute lymphoblastic leukemia at 10q26.13 and 12q23.1 OPEN

J Vijayakrishnan, R Kumar, M Y R Henrion, A V Moorman, P S Rachakonda, I Hosen, M I da Silva Filho, A Holroyd, S E Dobbins, R Koehler, H Thomsen, J A Irving, J M Allan, T Lightfoot, E Roman, S E Kinsey, E Sheridan, P D Thompson, P Hoffmann, M M Nöthen, S Heilmann-Heimbach, K H Jöckel, M Greaves, C J Harrison, C R Bartram, M Schrappe, M Stanulla, K Hemminki and R S Houlston

Leukemia 2017 31: 573-579; advance online publication, October 3, 2016; 10.1038/leu.2016.271

Abstract | Full Text

Long-term outcome of 6-month maintenance chemotherapy for acute lymphoblastic leukemia in children

M Kato, S Ishimaru, M Seki, K Yoshida, Y Shiraishi, K Chiba, N Kakiuchi, Y Sato, H Ueno, H Tanaka, T Inukai, D Tomizawa, D Hasegawa, T Osumi, Y Arakawa, T Aoki, M Okuya, K Kaizu, K Kato, Y Taneyama, H Goto, T Taki, M Takagi, M Sanada, K Koh, J Takita, S Miyano, S Ogawa, A Ohara, M Tsuchida and A Manabe

Leukemia 2017 31: 580-584; advance online publication, October 4, 2016; 10.1038/leu.2016.274

Abstract | Full Text


Cytogenetic landscape and impact in blast phase of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy

Z Chen, C Shao, W Wang, Z Zuo, X Mou, S J Hu, J A DiGiuseppe, Y Zu, L J Medeiros and S Hu

Leukemia 2017 31: 585-592; advance online publication, August 18, 2016; 10.1038/leu.2016.231

Abstract | Full Text

Treatment and outcome of 2904 CML patients from the EUTOS population-based registry

V S Hoffmann, M Baccarani, J Hasford, F Castagnetti, F Di Raimondo, L F Casado, A Turkina, D Zackova, G Ossenkoppele, A Zaritskey, M Höglund, B Simonsson, K Indrak, Z Sninska, T Sacha, R Clark, A Bogdanovic, A Hellmann, L Griskevicius, G Schubert-Fritschle, D Sertic, J Guilhot, S Lejniece, I Zupan, S Burgstaller, P Koskenvesa, H Everaus, P Costeas, D Lindoerfer, G Rosti, S Saussele, A Hochhaus and R Hehlmann

Leukemia 2017 31: 593-601; advance online publication, August 29, 2016; 10.1038/leu.2016.246

Abstract | Full Text


Inactivation of the putative ubiquitin-E3 ligase PDLIM2 in classical Hodgkin and anaplastic large cell lymphoma OPEN

K D Wurster, F Hummel, J Richter, M Giefing, S Hartmann, M-L Hansmann, S Kreher, K Köchert, D Krappmann, W Klapper, M Hummel, S-S Wenzel, G Lenz, M Janz, B Dörken, R Siebert and S Mathas

Leukemia 2017 31: 602-613; advance online publication, August 19, 2016; 10.1038/leu.2016.238

Abstract | Full Text

A role for MALT1 activity in Kaposi’s sarcoma-associated herpes virus latency and growth of primary effusion lymphoma OPEN

L Bonsignore, K Passelli, C Pelzer, M Perroud, A Konrad, M Thurau, M Stürzl, L Dai, J Trillo-Tinoco, L Del Valle, Z Qin and M Thome

Leukemia 2017 31: 614-624; advance online publication, August 19, 2016; 10.1038/leu.2016.239

Abstract | Full Text

Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma

Y Xia, Z Y Xu-Monette, A Tzankov, X Li, G C Manyam, V Murty, G Bhagat, S Zhang, L Pasqualucci, C Visco, K Dybkaer, A Chiu, A Orazi, Y Zu, K L Richards, E D Hsi, W W L Choi, J H van Krieken, J Huh, M Ponzoni, A J M Ferreri, M B Møller, B M Parsons, J N Winter, M A Piris, J Westin, N Fowler, R N Miranda, C Y Ok, Y Li, J Li, L J Medeiros and K H Young

Leukemia 2017 31: 625-636; advance online publication, September 30, 2016; 10.1038/leu.2016.243

Abstract | Full Text


Hyperhaploidy is a novel high-risk cytogenetic subgroup in multiple myeloma

J R Sawyer, E Tian, J D Shaughnessy Jr, J Epstein, C M Swanson, C Stangeby, C L Hale, L Parr, M Lynn, G Sammartino, J L Lukacs, C Stein, C Bailey, M Zangari, F E Davies, F Van Rhee, B Barlogie and G J Morgan

Leukemia 2017 31: 637-644; advance online publication, October 3, 2016; 10.1038/leu.2016.253

Abstract | Full Text

Pharmacogenomics and chemical library screens reveal a novel SCFSKP2 inhibitor that overcomes Bortezomib resistance in multiple myeloma OPEN

E Malek, M A Y Abdel-Malek, S Jagannathan, N Vad, R Karns, A G Jegga, A Broyl, M van Duin, P Sonneveld, F Cottini, K C Anderson and J J Driscoll

Leukemia 2017 31: 645-653; advance online publication, September 28, 2016; 10.1038/leu.2016.258

Abstract | Full Text


The proteome pattern cGvHD_MS14 allows early and accurate prediction of chronic GvHD after allogeneic stem cell transplantation

E M Weissinger, C Human, J Metzger, L Hambach, D Wolf, H T Greinix, A M Dickinson, W Mullen, D Jonigk, Z Kuzmina, H Kreipe, P Schweier, O Böhm, I Türüchanow, D Ihlenburg-Schwarz, J Raad, A Durban, M Schiemann, C Könecke, H Diedrich, E Holler, G Beutel, J Krauter, A Ganser and M Stadler

Leukemia 2017 31: 654-662; advance online publication, September 28, 2016; 10.1038/leu.2016.259

Abstract | Full Text

Impact of graft-versus-host disease on outcomes after unrelated cord blood transplantation

J Kanda, Y Morishima, S Terakura, A Wake, N Uchida, S Takahashi, Y Ono, Y Onishi, H Kanamori, N Aotsuka, Y Ozawa, H Ogawa, T Sakura, K Ohashi, T Ichinohe, K Kato, Y Atsuta, T Teshima and M Murata on behalf of the GVHD Working Group of the Japan Society for Hematopoietic Cell Transplantation

Leukemia 2017 31: 663-668; advance online publication, November 17, 2016; 10.1038/leu.2016.288

Abstract | Full Text


Phosphorylation of a constrained azacyclic FTY720 analog enhances anti-leukemic activity without inducing S1P receptor activation

A N McCracken, R J McMonigle, J Tessier, R Fransson, M S Perryman, B Chen, A Keebaugh, E Selwan, S A Barr, S M Kim, S G Roy, G Liu, D Fallegger, L Sernissi, C Brandt, N Moitessier, A J Snider, S Clare, M Müschen, A Huwiler, M T Kleinman, S Hanessian and A L Edinger

Leukemia 2017 31: 669-677; advance online publication, August 30, 2016; 10.1038/leu.2016.244

Abstract | Full Text

BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells

D T Saenz, W Fiskus, T Manshouri, K Rajapakshe, S Krieger, B Sun, C P Mill, C DiNardo, N Pemmaraju, T Kadia, S Parmar, S Sharma, C Coarfa, P Qiu, S Verstovsek and K N Bhalla

Leukemia 2017 31: 678-687; advance online publication, September 28, 2016; 10.1038/leu.2016.260

Abstract | Full Text

DOCK2 interacts with FLT3 and modulates the survival of FLT3-expressing leukemia cells

M Wu, M Hamaker, L Li, D Small and A S Duffield

Leukemia 2017 31: 688-696; advance online publication, October 17, 2016; 10.1038/leu.2016.284

Abstract | Full Text


PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies

M H Qazilbash, E Wieder, P F Thall, X Wang, R Rios, S Lu, S Kanodia, K E Ruisaard, S A Giralt, E H Estey, J Cortes, K V Komanduri, K Clise-Dwyer, G Alatrash, Q Ma, R E Champlin and J J Molldrem

Leukemia 2017 31: 697-704; advance online publication, September 22, 2016; 10.1038/leu.2016.254

Abstract | Full Text


The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases

A Stengel, W Kern, T Haferlach, M Meggendorfer, A Fasan and C Haferlach

Leukemia 2017 31: 705-711; advance online publication, September 29, 2016; 10.1038/leu.2016.263

Abstract | Full Text


The cohesin subunit Rad21 is a negative regulator of hematopoietic self-renewal through epigenetic repression of Hoxa7 and Hoxa9

J B Fisher, J Peterson, M Reimer, C Stelloh, K Pulakanti, Z J Gerbec, A M Abel, J M Strouse, C Strouse, M McNulty, S Malarkannan, J D Crispino, S Milanovich and S Rao

Leukemia 2017 31: 712-719; advance online publication, August 24, 2016; 10.1038/leu.2016.240

Abstract | Full Text


Hemopoietic-specific Sf3b1-K700E knock-in mice display the splicing defect seen in human MDS but develop anemia without ring sideroblasts OPEN

A Mupo, M Seiler, V Sathiaseelan, A Pance, Y Yang, A A Agrawal, F Iorio, R Bautista, S Pacharne, K Tzelepis, N Manes, P Wright, E Papaemmanuil, D G Kent, P C Campbell, S Buonamici, N Bolli and G S Vassiliou

Leukemia 2017 31: 720-727; advance online publication, September 8, 2016; 10.1038/leu.2016.251

Abstract | Full Text

Letters To The Editor


Prevalence and characteristics of survivors from acute myeloid leukemia in Sweden OPEN

G Juliusson, J Abrahamsson, V Lazarevic, P Antunovic, Å Derolf, H Garelius, S Lehmann, K Myhr-Eriksson, L Möllgård, B Uggla, A Wahlin, L Wennström, M Höglund and for the Swedish AML Group and the Swedish Childhood Leukemia Group

Leukemia 2017 31: 728-731; advance online publication, October 31, 2016; 10.1038/leu.2016.312

Full Text

Plastic CD34 and CD38 expression in adult B–cell precursor acute lymphoblastic leukemia explains ambiguity of leukemia-initiating stem cell populations OPEN

F Lang, B Wojcik, S Bothur, C Knecht, J H F Falkenburg, T Schroeder, H Serve, O G Ottmann and M A Rieger

Leukemia 2017 31: 731-734; advance online publication, November 2, 2016; 10.1038/leu.2016.315

Full Text

Frequent evolution of copy number alterations in CLL following first-line treatment with FC(R) is enriched with TP53 alterations: results from the CLL8 trial

J Edelmann, E Tausch, D A Landau, S Robrecht, J Bahlo, K Fischer, A M Fink, J Bloehdorn, K Holzmann, S Böttcher, L Werner, M Kneba, J G Gribben, D S Neuberg, C J Wu, M Hallek, H Döhner and S Stilgenbauer

Leukemia 2017 31: 734-738; advance online publication, November 2, 2016; 10.1038/leu.2016.317

Full Text

PD-L1 (CD274) promoter methylation predicts survival in patients with acute myeloid leukemia

D Goltz, H Gevensleben, S Grünen, J Dietrich, G Kristiansen, J Landsberg and D Dietrich

Leukemia 2017 31: 738-743; advance online publication, November 14, 2016; 10.1038/leu.2016.328

Full Text

Novel ALK fusion in anaplastic large cell lymphoma involving EEF1G, a subunit of the eukaryotic elongation factor-1 complex

G Palacios, T I Shaw, Y Li, R K Singh, M Valentine, J T Sandlund, M S Lim, C G Mullighan and V Leventaki

Leukemia 2017 31: 743-747; advance online publication, November 14, 2016; 10.1038/leu.2016.331

Full Text

The cryptic IRF2BP2-RARA fusion transforms hematopoietic stem/progenitor cells and induces retinoid-sensitive acute promyelocytic leukemia

J V Jovanovic, M C Chillón, C Vincent-Fabert, R Dillon, E Voisset, N C Gutiérrez, R G Sanz, A A M Lopez, Y G Morgan, J Lok, E Solomon, E Duprez, M G Díaz and D Grimwade

Leukemia 2017 31: 747-751; advance online publication, November 22, 2016; 10.1038/leu.2016.338

Full Text

Phosphatase PRL2 promotes oncogenic NOTCH1-Induced T-cell leukemia

M Kobayashi, Y Bai, S Chen, R Gao, C Yao, W Cai, A A Cardoso, J Croop, Z-Y Zhang and Y Liu

Leukemia 2017 31: 751-754; advance online publication, December 9, 2016; 10.1038/leu.2016.340

Full Text

Bcl-2 protein family expression pattern determines synergistic pro-apoptotic effects of BH3 mimetics with hemisynthetic cardiac glycoside UNBS1450 in acute myeloid leukemia OPEN

C Cerella, A Gaigneaux, A Mazumder, J-Y Lee, E Saland, F Radogna, T Farge, F Vergez, C Récher, J-E Sarry, K-W Kim, H Y Shin, M Dicato and M Diederich

Leukemia 2017 31: 755-759; advance online publication, November 22, 2016; 10.1038/leu.2016.341

Full Text

Mutational landscape in children with myelodysplastic syndromes is distinct from adults: specific somatic drivers and novel germline variants

V Pastor, S Hirabayashi, A Karow, J Wehrle, E J Kozyra, R Nienhold, G Ruzaike, D Lebrecht, A Yoshimi, M Niewisch, T Ripperger, G Göhring, I Baumann, S Schwarz, B Strahm, C Flotho, R C Skoda, C M Niemeyer and M W Wlodarski

Leukemia 2017 31: 759-762; advance online publication, November 23, 2016; 10.1038/leu.2016.342

Full Text

Diagnosis and relapse: cytogenetically normal acute myelogenous leukemia without FLT3-ITD or MLL-PTD

W Chien, Q-Y Sun, L-W Ding, A Mayakonda, S Takao, L Liu, S L Lim, K T Tan, M Garg, A De Sousa Maria Varela, J Xiao, N Jacob, K Behrens, C Stocking, M Lill, V Madan, N Hattori, S Gery, S Ogawa, S Wakita, T Ikezoe, L-Y Shih, T Alpermann, T Haferlach, H Yang and H P Koeffler

Leukemia 2017 31: 762-766; advance online publication, November 24, 2016; 10.1038/leu.2016.343

Full Text



Reply to Goel et al. ‘TP53 mutation allele-burden and disease outcome in MDS/AML’

D A Sallman, R Komrokji, A List and E Padron

Leukemia 2017 31: 767-768; advance online publication, October 14, 2016; 10.1038/leu.2016.257

Full Text

Response to Harrison et al. ‘Clinically relevant differences between BCSH and WHO diagnostic criteria for ET’ OPEN

H Gisslinger, G Jeryczynski, A Wölfler, C Beham-Schmid and J Thiele

Leukemia 2017 31: 768-769; advance online publication, November 29, 2016; 10.1038/leu.2016.319

Full Text

Response to ‘Overexpression of ABCB1 as prediction marker for CML: How close we are to translation into clinics?

L N Eadie, T P Hughes and D L White

Leukemia 2017 31: 769-770; advance online publication, December 2, 2016; 10.1038/leu.2016.335

Full Text

Cardiologist’s perspective to the European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia

C Constance, L Trudeau, E M Jolicoeur, D Langleben, A Rivard, R Chehayeb, M-A Côté and D Delgado

Leukemia 2017 31: 771-772; advance online publication, December 2, 2016; 10.1038/leu.2016.336

Full Text

Reply to Constance et al.

J L Steegmann, M Baccarani and R E Clark

Leukemia 2017 31: 772-773; advance online publication, December 6, 2016; 10.1038/leu.2016.337

Full Text



Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteria

H Gisslinger, G Jeryczynski, B Gisslinger, A Wölfler, S Burgstaller, V Buxhofer-Ausch, M Schalling, M-T Krauth, A-I Schiefer, C Kornauth, I Simonitsch-Klupp, C Beham-Schmid, L Müllauer and J Thiele

Leukemia 2017 31: 774-775; 10.1038/leu.2016.291

Full Text

Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis

C N Harrison, A M Vannucchi, J-J Kiladjian, H K Al-Ali, H Gisslinger, L Knoops, F Cervantes, M M Jones, K Sun, M McQuitty, V Stalbovskaya, P Gopalakrishna and T Barbui

Leukemia 2017 31: 775; 10.1038/leu.2016.323

Full Text

nature events
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here.

Find the latest scientific conferences, courses, meetings and symposia on For event advertising opportunities across the Nature Publishing Group portfolio please contact
More Nature Events

Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to Leukemia. In order to do so, please purchase a subscription.

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your account at: (You will need to log in to be recognised as a registrant).

For further technical assistance, please contact our registration department.

For print subscription enquiries, please contact our subscription department.

For other enquiries, please contact our customer feedback department.

Nature Publishing Group |One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA

Nature Publishing Group's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne
San Diego - San Francisco - Washington - New York - Boston

Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW.

© 2017 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.

nature publishing group

No comments: